{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:54:44Z","timestamp":1793973284683,"version":"4.8.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13148-019-0634-0","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T14:08:01Z","timestamp":1551708481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases"],"prefix":"10.1186","volume":"11","author":[{"given":"Wiphawan","family":"Wasenang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponlatham","family":"Chaiyarit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriporn","family":"Proungvitaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-4375","authenticated-orcid":false,"given":"Temduang","family":"Limpaiboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"key":"634_CR1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.pt.2012.07.006","volume":"28","author":"B Sripa","year":"2012","unstructured":"Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, et al. The tumorigenic liver fluke Opisthorchis viverrini\u2014multiple pathways to cancer. Trends Parasitol. 2012;28:395\u2013407.","journal-title":"Trends Parasitol"},{"key":"634_CR2","first-page":"1159","volume":"11","author":"HR Shin","year":"2010","unstructured":"Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang Y, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma\u2014focus on east and south-eastern Asia. Asian Pac J Cancer Prev. 2010;11:1159\u201366.","journal-title":"Asian Pac J Cancer Prev"},{"key":"634_CR3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.suc.2010.04.011","volume":"90","author":"GA Poultsides","year":"2010","unstructured":"Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90:817\u201337.","journal-title":"Surg Clin North Am"},{"key":"634_CR4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.dld.2009.12.008","volume":"42","author":"M Gatto","year":"2010","unstructured":"Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010;42:253\u201360.","journal-title":"Dig Liver Dis"},{"key":"634_CR5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000360507","volume":"32","author":"J Skipworth","year":"2014","unstructured":"Skipworth J, Keane M, Pereira S. Update on the management of cholangiocarcinoma. Dig Dis. 2014;32:570\u20138.","journal-title":"Dig Dis"},{"key":"634_CR6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cld.345","volume":"3","author":"JA Marrero","year":"2014","unstructured":"Marrero JA. Biomarkers in cholangiocarcinoma. Clin Liver Dis. 2014;3:101\u20133.","journal-title":"Clin Liver Dis"},{"key":"634_CR7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1148\/rg.284075148","volume":"28","author":"CO Menias","year":"2008","unstructured":"Menias CO, Surabhi VR, Prasad SR, Wang HL, Narra VR, Chintapalli KN. Mimics of cholangiocarcinoma: spectrum of disease. Radiographics. 2008;28:1115\u201329.","journal-title":"Radiographics."},{"key":"634_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4251\/wjgo.v3.i4.49","volume":"3","author":"G Malaguarnera","year":"2011","unstructured":"Malaguarnera G, Giordano M, Paladina I, Rando A, Uccello M, Basile F, et al. Markers of bile duct tumors. World J Gastrointest Oncol. 2011;3:49\u201359.","journal-title":"World J Gastrointest Oncol"},{"key":"634_CR9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2298\/SARH1506337I","volume":"143","author":"II Ignjatovic","year":"2015","unstructured":"Ignjatovic II, Matic SV, Dugalic VD, Knezevic DM, Micev MT, Bogdanovic MD, et al. A case of autoimmune cholangitis misdiagnosed for cholangiocarcinoma: how to avoid unnecessary surgical intervention? Srp Arh Celok Lek. 2015;143:337\u201340.","journal-title":"Srp Arh Celok Lek"},{"key":"634_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12893-016-0201-y","volume":"17","author":"N Rungsakulkij","year":"2017","unstructured":"Rungsakulkij N, Sornmayura P, Tannaphai P. Isolated IgG4-related sclerosing cholangitis misdiagnosed as malignancy in an area with endemic cholangiocarcinoma: a case report. BMC Surg. 2017;17:1\u20137.","journal-title":"BMC Surg"},{"key":"634_CR11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijscr.2013.10.017","volume":"5","author":"K Vasiliadis","year":"2014","unstructured":"Vasiliadis K, Fortounis K, Papavasiliou C, Kokarhidas A, Al Nimer A, Fachiridis D, et al. Mid common bile duct inflammatory pseudotumor mimicking cholangiocarcinoma. A case report and literature review. Int J Surg Case Rep. 2014;5:12\u20135.","journal-title":"Int J Surg Case Rep"},{"key":"634_CR12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0039-6060(99)70203-5","volume":"125","author":"A Nakayama","year":"1999","unstructured":"Nakayama A, Imamura H, Shimada R, Miyagawa S, Makuuchi M, Kawasaki S. Proximal bile duct stricture disguised as malignant neoplasm. Surgery. 1999;125:514\u201321.","journal-title":"Surgery."},{"key":"634_CR13","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1245\/s10434-007-9394-8","volume":"14","author":"TM Gulik van","year":"2007","unstructured":"van Gulik TM, Gouma DJ. Changing perspectives in the assessment of resectability of hilar cholangiocarcinoma. Ann Surg Oncol. 2007;14:1969\u201371.","journal-title":"Ann Surg Oncol"},{"key":"634_CR14","first-page":"109","volume":"64","author":"A Budzynska","year":"2013","unstructured":"Budzynska A, Nowakowska-Dulawa E, Marek T, Boldys H, Nowak A, Hartleb M. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin. J Physiol Pharmacol. 2013;64:109\u201314.","journal-title":"J Physiol Pharmacol"},{"key":"634_CR15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.27707","volume":"61","author":"K Andresen","year":"2015","unstructured":"Andresen K, Boberg KM, Vedeld HM, Honne H, Jebsen P, Hektoen M, et al. Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma. Hepatology. 2015;61:1651\u20139.","journal-title":"Hepatology."},{"key":"634_CR16","doi-asserted-by":"crossref","first-page":"e0150195","DOI":"10.1371\/journal.pone.0150195","volume":"11","author":"JB Rose","year":"2016","unstructured":"Rose JB, Correa-Gallego C, Li Y, Nelson J, Alseidi A, Helton WS, et al. The role of biliary carcinoembryonic antigen-related cellular adhesion molecule 6 (CEACAM6) as a biomarker in cholangiocarcinoma. PLoS One. 2016;11:e0150195.","journal-title":"PLoS One"},{"key":"634_CR17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-230X-9-30","volume":"9","author":"K Leelawat","year":"2009","unstructured":"Leelawat K, Sakchinabut S, Narong S, Wannaprasert J. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol. 2009;9:30.","journal-title":"BMC Gastroenterol"},{"key":"634_CR18","first-page":"6663","volume":"34","author":"F Lumachi","year":"2014","unstructured":"Lumachi F, Re GL, Tozzoli R, D\u2019Aurizio F, Facomer F, Chiara GB, et al. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study. Anticancer Res. 2014;34:6663\u20137.","journal-title":"Anticancer Res"},{"key":"634_CR19","doi-asserted-by":"crossref","first-page":"873548","DOI":"10.4061\/2011\/873548","volume":"2011","author":"K Leelawat","year":"2011","unstructured":"Leelawat K, Narong S, Wannaprasert J, Leelawat S. Serum NGAL to clinically distinguish cholangiocarcinoma from benign biliary tract diseases. Int J Hepatol. 2011;2011:873548.","journal-title":"Int J Hepatol"},{"key":"634_CR20","doi-asserted-by":"crossref","first-page":"18925","DOI":"10.3390\/ijms140918925","volume":"14","author":"YI Elshimali","year":"2013","unstructured":"Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013;14:18925\u201358.","journal-title":"Int J Mol Sci"},{"key":"634_CR21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415\u201328.","journal-title":"Nat Rev Genet"},{"key":"634_CR22","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1093\/hmg\/ddm018","volume":"16","author":"M Esteller","year":"2007","unstructured":"Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007;16:R50\u20139.","journal-title":"Hum Mol Genet"},{"key":"634_CR23","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2011.102","volume":"104","author":"R Sriraksa","year":"2011","unstructured":"Sriraksa R, Zeller C, El-Bahrawy M, Dai W, Daduang J, Jearanaikoon P, et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer. 2011;104:1313\u20138.","journal-title":"Br J Cancer"},{"key":"634_CR24","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s11596-013-1201-0","volume":"33","author":"W Li","year":"2013","unstructured":"Li W, Chen BF. Aberrant DNA methylation in human cancers. J Huazhong Univ Sci Technolog Med Sci. 2013;33:798\u2013804.","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"634_CR25","first-page":"464","volume":"28","author":"H Chen","year":"2006","unstructured":"Chen H, Ye F, Zhang J, Lu W, Cheng Q, Xie X. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma. Eur J Gynaecol Oncol. 2006;28:464\u20137.","journal-title":"Eur J Gynaecol Oncol"},{"key":"634_CR26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ng1183","volume":"34","author":"GC Sellar","year":"2003","unstructured":"Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet. 2003;34:337\u201343.","journal-title":"Nat Genet"},{"key":"634_CR27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1476-4598-6-70","volume":"6","author":"JA Tsou","year":"2007","unstructured":"Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, et al. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer. 2007;6:70.","journal-title":"Mol Cancer"},{"key":"634_CR28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2990.2006.00786.x","volume":"33","author":"J Reed","year":"2007","unstructured":"Reed J, Dunn JR, Du Plessis D, Shaw E, Reeves P, Gee A, et al. Expression of cellular adhesion molecule \u2018OPCML\u2019is down-regulated in gliomas and other brain tumours. Neuropathol Appl Neurobiol. 2007;33:77\u201385.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"634_CR29","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.ejca.2010.12.025","volume":"47","author":"S Duarte-Pereira","year":"2011","unstructured":"Duarte-Pereira S, Paiva F, Costa VL, Ramalho-Carvalho J, Savva-Bordalo J, Rodrigues A, et al. Prognostic value of opioid binding protein\/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur J Cancer. 2011;47:1106\u201314.","journal-title":"Eur J Cancer"},{"key":"634_CR30","first-page":"1635","volume":"5","author":"C Li","year":"2015","unstructured":"Li C, Tang L, Zhao L, Li L, Xiao Q, Luo X, et al. OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling. Am J Cancer Res. 2015;5:1635\u201348.","journal-title":"Am J Cancer Res"},{"key":"634_CR31","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1046\/j.0022-3042.2002.00798.x","volume":"80","author":"CJ McNamee","year":"2002","unstructured":"McNamee CJ, Reed JE, Howard MR, Lodge AP, Moss DJ. Promotion of neuronal cell adhesion by members of the IgLON family occurs in the absence of either support or modification of neurite outgrowth. J Neurochem. 2002;80:941\u20138.","journal-title":"J Neurochem"},{"key":"634_CR32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12885-017-3203-y","volume":"17","author":"X Xing","year":"2017","unstructured":"Xing X, Cai W, Ma S, Wang Y, Shi H, Li M, et al. Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer. BMC Cancer. 2017;17:268.","journal-title":"BMC Cancer"},{"key":"634_CR33","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1940-6207.CAPR-13-0104","volume":"6","author":"R Sriraksa","year":"2013","unstructured":"Sriraksa R, Zeller C, Dai W, Siddiq A, Walley AJ, Limpaiboon T, et al. Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer Prev Res. 2013;6:1348\u201355.","journal-title":"Cancer Prev Res"},{"key":"634_CR34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/molehr\/3.2.115","volume":"3","author":"B Favier","year":"1997","unstructured":"Favier B, Dolle P. Developmental functions of mammalian Hox genes. Mol Human Reprod. 1997;3:115\u201331.","journal-title":"Mol Human Reprod"},{"key":"634_CR35","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1940-6207.CAPR-11-0006","volume":"4","author":"R Guerrero-Preston","year":"2011","unstructured":"Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-Lopez L, Macia-Colon G, et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res. 2011;4:1061\u201372.","journal-title":"Cancer Prev Res"},{"key":"634_CR36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/1471-2407-14-353","volume":"14","author":"K Uchida","year":"2014","unstructured":"Uchida K, Veeramachaneni R, Huey B, Bhattacharya A, Schmidt BL, Albertson DG. Investigation of HOXA9 promoter methylation as a biomarker to distinguish oral cancer patients at low risk of neck metastasis. BMC Cancer. 2014;14:353.","journal-title":"BMC Cancer"},{"key":"634_CR37","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.1305172110","volume":"110","author":"M Sun","year":"2013","unstructured":"Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, et al. HMGA2\/TET1\/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U S A. 2013;110:9920\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"634_CR38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1476-4598-6-45","volume":"6","author":"Q Wu","year":"2007","unstructured":"Wu Q, Lothe RA, Ahlquist T, Silins I, Trop\u00e9 CG, Micci F, et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 2007;6:45.","journal-title":"Mol Cancer"},{"key":"634_CR39","doi-asserted-by":"crossref","first-page":"e46297","DOI":"10.1371\/journal.pone.0046297","volume":"7","author":"T Reinert","year":"2012","unstructured":"Reinert T, Borre M, Christiansen A, Hermann GG, \u00d8rntoft TF, Dyrskj\u00f8t L. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS One. 2012;7:e46297.","journal-title":"PLoS One"},{"key":"634_CR40","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.1002\/mc.22180","volume":"54","author":"JA Hwang","year":"2015","unstructured":"Hwang JA, Lee BB, Kim Y, Hong SH, Kim YH, Han J, et al. HOXA9 inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer. Mol Carcinog. 2015;54:E72\u201380.","journal-title":"Mol Carcinog"},{"key":"634_CR41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1242\/dev.122.2.461","volume":"122","author":"C Fromental-Ramain","year":"1996","unstructured":"Fromental-Ramain C, Warot X, Lakkaraju S, Favier B, Haack H, Birling C, et al. Specific and redundant functions of the paralogous Hoxa-9 and Hoxd-9 genes in forelimb and axial skeleton patterning. Development. 1996;122:461\u201372.","journal-title":"Development."},{"key":"634_CR42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1476-4598-10-60","volume":"10","author":"M Tabuse","year":"2011","unstructured":"Tabuse M, Ohta S, Ohashi Y, Fukaya R, Misawa A, Yoshida K, et al. Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Mol Cancer. 2011;10:60.","journal-title":"Mol Cancer"},{"key":"634_CR43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13046-015-0245-3","volume":"34","author":"X Lv","year":"2015","unstructured":"Lv X, Li L, Lv L, Qu X, Jin S, Li K, et al. HOXD9 promotes epithelial\u2013mesenchymal transition and cancer metastasis by ZEB1 regulation in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:133.","journal-title":"J Exp Clin Cancer Res"},{"key":"634_CR44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/hmg\/ddt420","volume":"23","author":"DM Marzese","year":"2013","unstructured":"Marzese DM, Scolyer RA, Huynh JL, Huang SK, Hirose H, Chong KK, et al. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet. 2013;23:226\u201338.","journal-title":"Hum Mol Genet"},{"key":"634_CR45","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1158\/0008-5472.CAN-09-3631","volume":"70","author":"X Wu","year":"2010","unstructured":"Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, et al. CpG island hypermethylation in human astrocytomas. Cancer Res. 2010;70:2718\u201327.","journal-title":"Cancer Res"},{"key":"634_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/jnai.2013.4282","volume":"4","author":"C Hufnagl","year":"2013","unstructured":"Hufnagl C, St\u00f6cher M, Moik M, Geisberger R, Greil R. A modified phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients. J Nucleic Acids. 2013;4:1.","journal-title":"J Nucleic Acids"},{"key":"634_CR47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-0500-1-54","volume":"1","author":"TK Wojdacz","year":"2008","unstructured":"Wojdacz TK, Hansen LL, Dobrovic A. A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes. 2008;1:54.","journal-title":"BMC Res Notes"},{"key":"634_CR48","first-page":"TC08","volume":"9","author":"M Suthar","year":"2015","unstructured":"Suthar M, Purohit S, Bhargav V, Goyal P. Role of MRCP in differentiation of benign and malignant causes of biliary obstruction. J Clin Diagn Res. 2015;9:TC08\u201312.","journal-title":"J Clin Diagn Res"},{"key":"634_CR49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5455\/aim.2016.24.257-260","volume":"24","author":"A Taheri","year":"2016","unstructured":"Taheri A, Rostamzadeh A, Gharib A, Fatehi D. Efficacy of multidetector-row computed tomography as a practical tool in comparison to invasive procedures for visualization of the biliary obstruction. Acta Inform Med. 2016;24:257\u201360.","journal-title":"Acta Inform Med"},{"key":"634_CR50","first-page":"103","volume":"8","author":"A Singh","year":"2014","unstructured":"Singh A, Mann HS, Thukral CL, Singh NR. Diagnostic accuracy of MRCP as compared to ultrasound\/CT in patients with obstructive jaundice. J Clin Diagn Res. 2014;8:103\u20137.","journal-title":"J Clin Diagn Res"},{"key":"634_CR51","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.crad.2014.01.001","volume":"69","author":"XR Yu","year":"2014","unstructured":"Yu XR, Huang WY, Zhang BY, Li HQ, Geng DY. Differentiation of infiltrative cholangiocarcinoma from benign common bile duct stricture using three-dimensional dynamic contrast-enhanced MRI with MRCP. Clin Radiol. 2014;69:567\u201373.","journal-title":"Clin Radiol"},{"key":"634_CR52","first-page":"105358","volume":"2015","author":"T Janvilisri","year":"2015","unstructured":"Janvilisri T, Leelawat K, Roytrakul S, Paemanee A, Tohtong R. Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach. Dis Markers. 2015;2015:105358.","journal-title":"Dis Markers"},{"key":"634_CR53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jcb.21661","volume":"104","author":"L Liu","year":"2008","unstructured":"Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, et al. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem. 2008;104:745\u201355.","journal-title":"J Cell Biochem"},{"key":"634_CR54","doi-asserted-by":"crossref","first-page":"9821","DOI":"10.1073\/pnas.93.18.9821","volume":"93","author":"JG Herman","year":"1996","unstructured":"Herman JG, Graff JR, My\u00f6h\u00e4nen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"634_CR55","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/meth.2001.1268","volume":"25","author":"BN Trinh","year":"2001","unstructured":"Trinh BN, Long TI, Laird PW. DNA methylation analysis by MethyLight technology. Methods. 2001;25:456\u201362.","journal-title":"Methods."},{"key":"634_CR56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3844\/ajbbsp.2012.14.20","volume":"8","author":"M Fakruddin","year":"2012","unstructured":"Fakruddin M, Chowdhury A. Pyrosequencing an alternative to traditional sanger sequencing. Am J Biochem Biotechnol. 2012;8:14\u201320.","journal-title":"Am J Biochem Biotechnol"},{"key":"634_CR57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/erm.10.46","volume":"10","author":"TK Wojdacz","year":"2010","unstructured":"Wojdacz TK, M\u00f8ller TH, Thestrup BB, Kristensen LS, Hansen LL. Limitations and advantages of MS-HRM and bisulfite sequencing for single locus methylation studies. Exert Rev Mol Diagn. 2010;10:575\u201380.","journal-title":"Exert Rev Mol Diagn"},{"key":"634_CR58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4236\/eng.2012.410B027","volume":"5","author":"Y Du","year":"2012","unstructured":"Du Y, Zhou Y, Wu Q. MS-HRM to detect serum DNA methylation of intrauterine growth retardation children. Engineering. 2012;5:106\u20139.","journal-title":"Engineering."},{"key":"634_CR59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.placenta.2016.06.003","volume":"44","author":"B Rahat","year":"2016","unstructured":"Rahat B, Thakur S, Bagga R, Kaur J. Epigenetic regulation of STAT5A and its role as fetal DNA epigenetic marker during placental development and dysfunction. Placenta. 2016;44:46\u201353.","journal-title":"Placenta."},{"key":"634_CR60","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1002\/ijc.29192","volume":"136","author":"X Yang","year":"2015","unstructured":"Yang X, Dai W, Kwong DL, Szeto CY, Wong EH, Ng WT, et al. Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. Int J Cancer. 2015;136:E127\u201335.","journal-title":"Int J Cancer"},{"key":"634_CR61","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/JCM.01709-12","volume":"50","author":"SY Tong","year":"2012","unstructured":"Tong SY, Giffard PM. Clinical microbiological applications of high-resolution melting analysis. J Clin Microbiol. 2012;50:3418\u201321.","journal-title":"J Clin Microbiol"},{"key":"634_CR62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13058-015-0645-5","volume":"7","author":"H Schwarzenbach","year":"2015","unstructured":"Schwarzenbach H, Pantel K. Circulating DNA as biomarker in breast cancer. Breast Cancer Res. 2015;7:136.","journal-title":"Breast Cancer Res"},{"key":"634_CR63","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.4238\/2015.May.4.11","volume":"14","author":"B Xing","year":"2015","unstructured":"Xing B, Li T, Tang Z, Jiao L, Ge S, Qiang X, et al. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer. Gen Mol Res. 2015;14:4532\u201340.","journal-title":"Gen Mol Res"},{"key":"634_CR64","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1007\/s13277-015-3147-2","volume":"36","author":"R Amornpisutt","year":"2015","unstructured":"Amornpisutt R, Proungvitaya S, Jearanaikoon P, Limpaiboon T. DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma. Tumor Biol. 2015;36:4973\u20138.","journal-title":"Tumor Biol"},{"key":"634_CR65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/15592294.2016.1148867","volume":"11","author":"Y Wu","year":"2016","unstructured":"Wu Y, Davison J, Qu X, Morrissey C, Storer B, Brown L, et al. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer. Epigenetics. 2016;11:247\u201358.","journal-title":"Epigenetics."},{"key":"634_CR66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3892\/ol.2017.6111","volume":"14","author":"B Wang","year":"2017","unstructured":"Wang B, Yu L, Luo X, Huang L, Li QS, Shao XS, et al. Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. Oncol Lett. 2017;14:217\u201323.","journal-title":"Oncol Lett"},{"key":"634_CR67","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7754\/Clin.Lab.2013.130446","volume":"60","author":"F Zhou","year":"2014","unstructured":"Zhou F, Ma M, Tao G, Chen X, Xie W, Wang Y, et al. Detection of circulating methylated opioid binding protein\/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma. Clin Lab. 2014;60:759\u201365.","journal-title":"Clin Lab"},{"key":"634_CR68","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-11-0256","volume":"2","author":"AB McKie","year":"2012","unstructured":"McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, et al. The OPCML tumor suppressor functions as a cell surface repressor\u2013adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov. 2012;2:156\u201371.","journal-title":"Cancer Discov"},{"key":"634_CR69","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-17-0081","volume":"16","author":"E Zanini","year":"2017","unstructured":"Zanini E, Louis LS, Antony J, Karali E, Okon IS, McKie AB, et al. The tumor suppressor protein OPCML potentiates anti-EGFR and anti-HER2 targeted therapy in HER2-positive ovarian and breast cancer. Mol Cancer Ther. 2017;16:2246\u201356.","journal-title":"Mol Cancer Ther"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-019-0634-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-019-0634-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-019-0634-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T23:44:38Z","timestamp":1663026278000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-019-0634-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1186\/s13148-019-0634-0","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"13 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Wiphawan Wasenang received her B. Medical Technology from Khon Kaen University, Khon Kaen, Thailand in 2011. She is currently a Ph.D. student in Biomedical Sciences program in Khon Kaen University, Khon Kaen, Thailand under guidance of Prof. Temduang Limpaiboon. She is working on cancer genetics and epigenetics in CCA for finding biomarkers and novel therapeutic drugs for the treatment.Ponlatham Chaiyarit received his Ph.D. degree in Dental Science from Indiana University, USA. He is an Associate Professor at Department of Oral Diagnosis and also the director of Chronic Inflammatory Oral Disease Research Group at Faculty of Dentistry, Khon Kaen University, Thailand. His research work has been focused on two aspects: the first aspect is the pathogenesis of oral diseases such as oral lichen planus and oral cancer. The second aspect is saliva research for the diagnostics and monitoring device for personalized health care.Siriporn Proungvitaya received her Ph.D. in Medical Sciences from Kumamoto University, Japan. Currently, she is an Associate Professor at the Department of Clinical Chemistry and also a senior advisor of cancer research group at the Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand. Her research work has been focused on proteomics for cholangiocarcinoma diagnosis.Temduang Limpaiboon received her Ph.D. in Biochemistry from the University of Queensland, Australia in 1991. She was a JSPS visiting scientist in Tumor Biology at Kumamoto University School of Medicine, Japan in 1995 and in Molecular Oncology at Chiba Cancer Center Research Institute, Japan in 2002. Currently, she is a Professor at the Department of Clinical Chemistry, and a leader of cancer research group at the Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand. Prof. Limpaiboon\u2019s laboratory focuses on cancer epigenetics, molecular biomarkers, and tumor biology of cholangiocarcinoma and cervical cancer. Her research activities also include 3-D scaffolds for cancer culture and tumor biology, biomimetic materials for cartilage tissue engineering and regenerative medicine, and nanomedicine. She supervised 7 PhD and 9 MSc, and co-supervised around 40 PhD and MSc students to completion. She currently supervises 5 PhD and 1 MSc, and co-supervises about 20 PhD and MSC students.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"This study was approved by the Khon Kaen University Ethics Committee for Human Research. The reference number was HE551066.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"39"}}